{
    "nct_id": "NCT05428969",
    "official_title": "A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia",
    "inclusion_criteria": "* Patient ≥ 18 years of age who presents with one of the following conditions:\n\n  * Morphologically confirmed diagnosis of MDS with revised International Prognostic Scoring System (rIPSS) risk categories: intermediate, high and very high.\n  * Morphologically confirmed diagnosis of CMML-2 with indication for azacitidine treatment.\n  * CMML and MDS patient with response failure to HMA or therapy regimen including HMA.\n  * Morphologically confirmed diagnosis of r/r AML following at least 1 line of prior therapies with indication for azacitidine treatment.\n  * Morphologically confirmed diagnosis of AML in patients unfit for induction therapy with indication for azacitidine-venetoclax treatment.\n* Leukocyte count < 20 x10^9/L (< 25 x10^9/L for newly diagnosed AML). Hydroxycarbamide use is permitted to meet this criterion in MDS and AML but not in CMML.\n* Adequate renal function.\n* Adequate liver function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient with acute promyelocytic leukemia (APL) or myeloproliferative CMML as defined by leukocyte count > 13 x10^9/L.\n* Eastern Cooperative Oncology Group (ECOG) performance status >2 (except newly diagnosed AML where ECOG 3 is allowed for patients < 75 years).\n* Allogeneic transplantation less than 6 months prior screening.\n* Patient with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).\n* The patient requires systemic corticosteroid (≥10 mg/day prednisone or equivalent) or other immunosuppressive treatment.\n* Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than 14 days or five half-lives (whichever is shorter) from a small molecule targeted therapy or oral anticancer chemotherapy before the first study treatment.\n* Any immunotherapy or investigational therapy within preceding 28 days from the first study treatment.\n* Pregnant or lactating women.\n* History of chronic ulcers or clinically relevant liver disease leading to Child Pugh Score C or higher.",
    "miscellaneous_criteria": ""
}